BRISTOL-MYERS SQUIBB COMPANY Marketable Securities, Gain (Loss)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Marketable Securities, Gain (Loss) of $745.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-09.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLoss · last filed 2022-02-09
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for the quarter ending 2020-12-31 was $504.00M, a 73.79% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for the quarter ending 2020-09-30 was $244.00M.
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for the quarter ending 2020-06-30 was $818.00M, a 1052.11% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for the quarter ending 2020-03-31 was -$339.00M, a 293.71% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for fiscal 2021 was $745.00M, a 39.33% decline from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for fiscal 2020 was $1.23B, a 346.55% increase from fiscal 2019.
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for fiscal 2019 was $275.00M.
- BRISTOL-MYERS SQUIBB COMPANY marketable securities, gain (loss) for fiscal 2018 was -$419.00M, a 1921.74% decline from fiscal 2017.
| Period end | Marketable Securities, Gain (Loss) 3 month | Marketable Securities, Gain (Loss) 3 month as first filed | Marketable Securities, Gain (Loss) 6 month | Marketable Securities, Gain (Loss) 6 month as first filed | Marketable Securities, Gain (Loss) 9 month | Marketable Securities, Gain (Loss) 9 month as first filed | Marketable Securities, Gain (Loss) 12 month | Marketable Securities, Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $745.00M 10-K · filed 2022-02-09 | |||||||
| 2020-12-31 | $504.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $748.00M derived: sum of 2 quarters · filed 2022-02-09 | $1.57B derived: sum of 3 quarters · filed 2022-02-09 | $1.23B 10-K · filed 2022-02-09 | ||||
| 2020-09-30 | $244.00M 10-Q · filed 2020-11-05 | $1.06B derived: sum of 2 quarters · filed 2020-11-05 | $724.00M 10-Q · filed 2020-11-05 | $1.01B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $818.00M 10-Q · filed 2020-08-06 | $479.00M 10-Q · filed 2020-08-06 | $769.00M derived: sum of 3 quarters · filed 2022-02-09 | $508.00M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | -$339.00M 10-Q · filed 2020-05-07 | -$49.00M derived: sum of 2 quarters · filed 2022-02-09 | -$310.00M derived: sum of 3 quarters · filed 2022-02-09 | -$239.00M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $290.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $29.00M derived: sum of 2 quarters · filed 2022-02-09 | $100.00M derived: sum of 3 quarters · filed 2022-02-09 | $275.00M 10-K · filed 2022-02-09 | $279.00M 10-K · filed 2020-02-24 | |||
| 2019-09-30 | -$261.00M 10-Q · filed 2020-11-05 | -$190.00M derived: sum of 2 quarters · filed 2020-11-05 | -$15.00M 10-Q · filed 2020-11-05 | -$190.00M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-06-30 | $71.00M 10-Q · filed 2020-08-06 | $246.00M 10-Q · filed 2020-08-06 | $71.00M derived: sum of 3 quarters · filed 2021-02-10 | $168.00M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-03-31 | $175.00M 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-02-10 | $97.00M derived: sum of 3 quarters · filed 2021-02-10 | -$259.00M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2018-12-31 | -$175.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | -$78.00M derived: sum of 2 quarters · filed 2021-02-10 | -$434.00M derived: sum of 3 quarters · filed 2021-02-10 | -$419.00M 10-K · filed 2021-02-10 | -$512.00M 10-K · filed 2019-02-25 | |||
| 2018-09-30 | $97.00M 10-Q · filed 2019-10-31 | -$259.00M derived: sum of 2 quarters · filed 2019-10-31 | -$244.00M 10-Q · filed 2019-10-31 | -$262.00M 10-Q · filed 2018-10-25 | ||||
| 2018-06-30 | -$356.00M 10-Q · filed 2019-07-25 | -$374.00M 10-Q · filed 2018-07-26 | -$341.00M 10-Q · filed 2019-07-25 | -$359.00M 10-Q · filed 2018-07-26 | ||||
| 2018-03-31 | $15.00M 10-Q · filed 2019-04-25 | |||||||
| 2017-12-31 | $23.00M 10-K · filed 2020-02-24 | |||||||
| 2016-12-31 | -$37.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |